Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SPRY ARS Pharmaceuticals
7.470-0.180-2.35%
Close
02/08 16:00 ET
7.4700.0000.00%
Post Mkt Price 02/08 19:59 ET
High
7.885
Open
7.620
Turnover
1.95M
Low
7.240
Pre Close
7.650
Volume
259.81K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Wedbush Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Wedbush assumed coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) in a report issued on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $10
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
UpgradesFor Silvercorp Metals Inc (AMEX:SVM), Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in the
Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market
07:37 AM EST, 01/31/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
ARS Pharmaceuticals Price Target Announced at $10.00/Share by Wedbush
ARS Pharmaceuticals Price Target Announced at $10.00/Share by Wedbush
Wedbush Initiates Coverage On ARS Pharmaceuticals With Outperform Rating, Announces Price Target of $10
Wedbush analyst Andreas Argyrides initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and announces Price Target of $10.
ARS Pharmaceuticals (SPRY) Receives a New Rating From Wedbush
ARS Pharmaceuticals Initiated With an Outperform at Wedbush
SVB Leerink Comments on ARS Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:SPRY)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) – Research analysts at SVB Leerink increased their FY2026 earnings estimates for shares of ARS Pharmaceuticals in a report released on Friday,
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 1.2%
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) was down 1.2% during mid-day trading on Thursday . The company traded as low as $6.33 and last traded at $6.40. Approximately 145,504 shares trade
ARS Pharmaceuticals (SPRY) Gets a Buy From SVB Securities
